Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) (NCT05224141)
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.
Who can join: Review the eligibility criteria below.
Location: Infirmary Cancer Care ( Site 0022) — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (140 Sites)
Showing the first 25 of 140 sites.
- Infirmary Cancer Care ( Site 0022) — Mobile, Alabama
- Los Angeles Hematology Oncology Medical Group ( Site 0006) — Los Angeles, California
- VA West Los Angeles Medical Center ( Site 0004) — Los Angeles, California
- Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014) — Boca Raton, Florida
- Fort Wayne Medical Oncology and Hematology ( Site 0013) — Fort Wayne, Indiana
- Dana-Farber Cancer Institute ( Site 0018) — Boston, Massachusetts
- Cancer and Hematology Centers of Western Michigan ( Site 0001) — Grand Rapids, Michigan
- Hattiesburg Clinic Hematology/Oncology ( Site 0003) — Hattiesburg, Mississippi
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0005) — Lancaster, Pennsylvania
- Blue Ridge Cancer Care ( Site 0015) — Blacksburg, Virginia
- University of Virginia Cancer Center ( Site 0019) — Charlottesville, Virginia
- Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0203) — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201) — Mar del Plata, Buenos Aires
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0200) — Buenos Aires, Buenos Aires F.D.
- Hospital Provincial del Centenario ( Site 0205) — Rosario, Santa Fe Province
- Sanatorio Parque ( Site 0202) — Rosario, Santa Fe Province
- Nepean Hospital ( Site 2700) — Kingswood, New South Wales
- Calvary Mater Newcastle ( Site 2703) — Waratah, New South Wales
- Frankston Hospital-Oncology and Haematology ( Site 2702) — Frankston, Victoria
- Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 2701) — Melbourne, Victoria
- Medizinische Universität Graz ( Site 0504) — Graz, Styria
- Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0505) — Linz, Upper Austria
- Kepler Universitätsklinikum ( Site 0507) — Linz, Upper Austria
- Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 0502) — Vienna,
- Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0501) — Vienna,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Carcinoma
- Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) — Duarte, California
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) — Gilbert, Arizona
- Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors — Iowa City, Iowa
- DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers — Mobile, Alabama
Explore by condition: All Small Cell Lung Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.